Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
10.09. | Editor's Corner-For the first PD-1xVEGF's sake, Summit must submit to Big Pharma, stat | ||
10.09. | For pharmas looking to 'break through the clutter' and reach patients, relatability is the key | ||
10.09. | 'Land mines everywhere': How pharma communications keep up under a political spotlight | ||
10.09. | Sanofi rounds up 'celebrity mom squad' for Beyfortus RSV campaign | ||
10.09. | Trump directs FDA to limit DTC drug advertising, with legal challenges sure to follow | ||
10.09. | J&J's 'practice-changing' bladder cancer drug-device combo Inlexzo lands FDA nod | ||
10.09. | Trump admin mulls 'severe restrictions' on US pharmas licensing Chinese meds: NYT | ||
10.09. | Eli Lilly gives Julianne Moore a new role, signing up Oscar winner for brain health campaign | ||
10.09. | Novo Nordisk to lay off 9,000 workers as new CEO aims to save $1.3B per year by late 2026 | ||
10.09. | Takeda faces another 'pay-for-delay' antitrust lawsuit, this one from CVS over heartburn drug Dexilant | ||
09.09. | 'We want to feel heard': Jamie-Lynn Sigler on how pharmas can better serve patients | ||
09.09. | Lundbeck, in major resource reallocation, bows out of 27 markets and lays off 602 staffers | ||
09.09. | Permira looks to launch $4B sale of CDMO Cambrex: FT | ||
09.09. | Novo, Lilly obesity meds 'highly cost-effective' but sure to strain payer budgets: ICER report | ||
09.09. | With settlement, Sandoz can launch its biosimilar to Regeneron's Eylea by end of 2026 | ||
09.09. | Endo touts Xiaflex success stories in inaugural Dupuytren's contracture awareness month | ||
09.09. | Amid tariff uncertainty, Korea's Samsung Biologics inks $1.3B contract manufacturing deal with US pharma | ||
08.09. | Trump carves out generics from 15% tariffs in US-Japan trade deal | ||
08.09. | With 'compelling' effect size, Eli Lilly's Jaypirca advances a step closer to first-line use in CLL | ||
05.09. | RFK Jr. plans to link Tylenol use during pregnancy to autism, WSJ reports; Kenvue shares tumble | ||
05.09. | Point-of-care pharma marketing spending passes $1B milestone | ||
05.09. | Astellas attacks menopause stigma with new workplace inclusivity program | ||
05.09. | Perrigo, undergoing strategy shift, moves to replace striking workers at NYC plant: report | ||
05.09. | Europe warns consumers about 'sharp rise' in counterfeit versions of Novo, Lilly weight loss drugs | ||
05.09. | Seeking royalties, GSK expands mRNA patent litigation to include Moderna's next-generation COVID shot |